Agile Therapeutics Price to Free Cash Flow Ratio 2013-2023 | AGRX
Historical price to free cash flow ratio values for Agile Therapeutics (AGRX) since 2013.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Agile Therapeutics Price to Free Cash Flow Ratio Historical Data |
Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
2024-03-25 |
0.60 |
|
0.00 |
2023-12-31 |
1.95 |
$-4.44 |
0.00 |
2023-09-30 |
2.40 |
$-40.13 |
0.00 |
2023-06-30 |
2.95 |
$108.34 |
0.03 |
2023-03-31 |
11.20 |
$153.56 |
0.07 |
2022-12-31 |
11.35 |
$-83.48 |
0.00 |
2022-09-30 |
14.85 |
$-354.62 |
0.00 |
2022-06-30 |
58.25 |
$-866.51 |
0.00 |
2022-03-31 |
419.00 |
$-1,251.29 |
0.00 |
2021-12-31 |
976.20 |
$-1,348.92 |
0.00 |
2021-09-30 |
1922.20 |
$-1,473.69 |
0.00 |
2021-06-30 |
2660.00 |
$-1,464.64 |
0.00 |
2021-03-31 |
4160.00 |
$-1,252.12 |
0.00 |
2020-12-31 |
5740.00 |
$-1,125.70 |
0.00 |
2020-09-30 |
6080.00 |
$-867.25 |
0.00 |
2020-06-30 |
5560.00 |
$-644.43 |
0.00 |
2020-03-31 |
3720.00 |
$-582.77 |
0.00 |
2019-12-31 |
5000.00 |
$-638.73 |
0.00 |
2019-09-30 |
2370.00 |
$-648.67 |
0.00 |
2019-06-30 |
2920.00 |
$-741.96 |
0.00 |
2019-03-31 |
3020.00 |
$-919.04 |
0.00 |
2018-12-31 |
1151.80 |
$-1,003.21 |
0.00 |
2018-09-30 |
733.00 |
$-1,268.96 |
0.00 |
2018-06-30 |
988.00 |
$-1,410.06 |
0.00 |
2018-03-31 |
5140.00 |
$-1,604.51 |
0.00 |
2017-12-31 |
5380.00 |
$-1,672.42 |
0.00 |
2017-09-30 |
8920.00 |
$-1,453.54 |
0.00 |
2017-06-30 |
7500.00 |
$-1,603.57 |
0.00 |
2017-03-31 |
6410.00 |
$-1,565.91 |
0.00 |
2016-12-31 |
11400.00 |
$-1,650.46 |
0.00 |
2016-09-30 |
13960.00 |
$-1,901.49 |
0.00 |
2016-06-30 |
15220.00 |
$-2,033.33 |
0.00 |
2016-03-31 |
12420.00 |
$-2,294.96 |
0.00 |
2015-12-31 |
19520.00 |
$-2,340.71 |
0.00 |
2015-09-30 |
13480.00 |
$-3,449.23 |
0.00 |
2015-06-30 |
17180.00 |
$-3,470.71 |
0.00 |
2015-03-31 |
18540.00 |
$-3,110.68 |
0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|